ArticleScientific reports2025
Integrated metabolomics and lipidomics reveal fatty acid dysregulation in aortic dissection independent of hypertension.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Aortic dissection (AD), characterized by rupture of the aortic wall, presents significant diagnostic challenges due to its rapid onset and nonspecific clinical symptoms. Although conventional imaging techniques are clinically useful, they typically lack sensitivity for early AD detection, are often unavailable in resource-limited settings, and cannot elucidate the mechanistic basis of AD pathogenesis. In this study, we used metabolomics and lipidomics to analyze serum samples from healthy controls, hypertensive AD patients, and normotensive AD patients, revealing distinct metabolic and lipidomic perturbations associated with AD, independent of blood pressure status. Notably, mitochondrial dysfunction was a pivotal factor in AD pathogenesis, and key metabolites such as acetylcarnitine served as both an AD biomarker and an indicator of disrupted lipid metabolism. Lipidomic profiling further revealed a consistent accumulation of specific fatty acids in AD patients, including elevated levels of FA(16:1), FA(20:1), FA(22:5), and FA(20:2) in both hypertensive and normotensive subgroups. Additionally, the sphingolipid signaling pathway was the most markedly altered lipidomic pathway between the two AD groups. These findings offer new insights into the complex lipidomic and metabolic mechanisms underlying AD pathogenesis, paving the way for improved diagnostics and targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.